OUR TEAM
A multidisciplinary team of Engineers, Doctors, Pharma Experts and AI pioneers, relentlessly advancing wearable cardiac diagnostics. Together, we’re turning science into life-saving solutions.
Satya Tatavarthy: President & Founder Experience: 25+ years Domain: Energy, Clean tech & Health tech
Srujana Kapavarapu: Director Experience: 18+ years Domain: Biotechnology, Clinical Trials
Dr. Emer MacSweeney: Advisor CEO of Re:Cognition Health, UK, Advisor Experience: 35+ years Domain: Neuroradiology, Alzheimer’s disease, CTE
Dr. Seshu Babu Vinjamuri: Advisor Doctor of Medicine (M.D) Experience: 35+ years Domain: Public health, Infectious disease contro
Sirisha Damaraju: Director Experience: 14+ years Domain: HR, Learning & Development, Recruitment
Features
Get lab-accurate results in minutes with our wearable that tracks multiple biomarkers simultaneously, then instantly shares encrypted data with your care team. One device delivers complete, actionable heart health insights faster than traditional methods.
Results within minutes
Get life-saving cardiac results in minutes—not hours. Our breakthrough technology delivers lab-accurate troponin and ECG readings anywhere, empowering faster treatment decisions when every second counts.
One Wearable. Multiple Biomarkers. Smarter Heart Monitoring.
Consolidate your cardiac care. One wearable continuously analyzes multiple critical biomarkers, giving clinicians and patients unparalleled heart health visibility.
Sharable Test results
Test Results That Move as Fast as You Need Them To – Securely share ER-grade cardiac data with physicians, specialists or family with one tap.
Key Milestones
Each of these carefully planned milestones brings us closer to revolutionizing cardiac care through accessible, wearable diagnostics. We're not just developing technology - we're creating a new standard for proactive heart health monitoring that will benefit patients and clinicians worldwide.
U-Tropia’s 2025 Development Pathway
Since our successful April 2024 launch demonstrating Troponin I & Myoglobin detection, we’ve been making rapid progress. By Q3 2025, we’ll secure Series A funding